trial · primary record
Nipocalimab
Lupus Erythematosus, Systemic
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 600 |
| Primary completion | 2031-11-07 |
| Primary endpoint | Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI)-4 Composite Response at Week 52 |
| Registry ID | NCT07438496 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:13.337Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07438496
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Nipocalimab · compound